65796-52-3

Basic information

• Product Name: 2,3,4,9-tetrahydro-1H-carbazol-6-amine
• Synonyms: 2,3,4,9-tetrahydro-1H-carbazol-6-amine;6,7,8,9-tetrahydro-5H-carbazol-3-amine
• CAS NO: 65796-52-3
• Molecular Formula: C₁₂H₁₄N₂
• Molecular Weight: 186.25296
• Mol File: 65796-52-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 151-152 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 403.7°C at 760 mmHg
• Flash Point: 226.9°C
• Appearance: /
• Density: 1.233g/cm³
• Vapor Pressure: 9.96E-07mmHg at 25°C
• Refractive Index: 1.718
• PKA: 18.24±0.20(Predicted)
• CAS DataBase Reference: 2,3,4,9-tetrahydro-1H-carbazol-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,9-tetrahydro-1H-carbazol-6-amine(65796-52-3)
• EPA Substance Registry System: 2,3,4,9-tetrahydro-1H-carbazol-6-amine(65796-52-3)

Safety Data

• Hazardous Substances Data: 65796-52-3(Hazardous Substances Data)

Usage

General Description

2,3,4,9-tetrahydro-1H-carbazol-6-amine is a chemical compound that belongs to the carbazole class of compounds. It is a derivative of carbazole and contains an amine functional group. 2,3,4,9-tetrahydro-1H-carbazol-6-amine has potential biological and pharmacological activities due to its structure and properties, making it a subject of interest in medicinal chemistry and drug discovery. Additionally, it may have applications in organic synthesis and as a building block for the synthesis of other compounds due to its unique structure and reactivity. Further research and exploration of its properties and potential applications are warranted to fully understand and harness its capabilities.

InChI:InChI=1/C12H14N2/c13-8-5-6-12-10(7-8)9-3-1-2-4-11(9)14-12/h5-7,14H,1-4,13H2

Upstream product

• 50823-86-4 6-nitro-2,3,4,9-tetrahydro-1H-carbazole 
• 109690-31-5 N-(5,6,7,8-tetrahydro-carbazol-3-yl)-acetamide 
• 636-99-7 4-nitrophenylhydrazine hydrochloride 
• 3077-85-8 3-Nitro-carbazol 
• 100-63-0 phenylhydrazine 
• 942-01-8 1,2,3,4-tetrahydrocarbazole 
• 100-16-3 4-nitrophenylhydrazone 
• 108-94-1 cyclohexanone 

Downstream Products

• 6377-12-4 3-amino-9H-carbazole 
• 1240-34-2 4-methyl-N-(2,3,4,9-tetrahydro-1H-carbazol-6-yl)benzenesulfonamide 
• 110146-03-7 N-(2,3,4,9-tetrahydro-1H-carbazol-6-yl)benzamide 

Relevant articles and documents

Synthesis and evaluation of 2,3,4,9-tetrahydro-1H-carbazole derivatives as selective acetylcholinesterase inhibitors: Potential anti-Alzheimer's agents

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and cognition skills. Dysfunction of acetylcholine containing neurons in the brain contributes substantially to the cognitive decline observed in Alzheimer's disease. Hence, our focus is to synthesize cholinesterase inhibitors. A series (22 compounds) of 6- and 9-substituted derivatives of 2,3,4,9-tetrahydro-1H-carbazole have been prepared and in vitro evaluated for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition by Ellman's method. By comparing selectivity with standard drug donepezil, amino derivative 3, methylamino derivative 4 and butyl nitro derivative 17 have been found to be selective AChE inhibitors. Borsche-Drechsel cyclization reaction has been carried out to synthesize 2,3,4,9-tetrahydrocarbazole ring followed by nitration, reduction and derivative synthesis.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.